At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 22 target
Drug / intervention
Apatinib Mesylate, Gefitinibdrug
Likely dose
Apatinib Mesylate, Gefitinib 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open-label, Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous, Non-small-cell Lung Cancer Patients
In Brief
A Phase 1 clinical trial evaluating Apatinib Mesylate, Gefitinib for NSCLC. Targeting 22 participants across 1 site.
Detailed Summary
The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients. The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202120222023202420252026
First PostedMay 2020
Enrollment StartMay 2020
Primary CompletionFeb 2021
Study CompletionMar 2021
TodayJul 2026
First PostedMay 18, 2020
Enrollment StartMay 26, 2020
Primary CompletionFeb 1, 2021
Study CompletionMar 1, 2021
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 6.1 years ago
Interventions
Apatinib Mesylate, Gefitinibdrug
Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.